43.36
1.16 (2.75%)
| Penutupan Terdahulu | 42.20 |
| Buka | 42.30 |
| Jumlah Dagangan | 1,212,246 |
| Purata Dagangan (3B) | 1,945,517 |
| Modal Pasaran | 3,431,508,480 |
| Harga / Buku (P/B) | 5.38 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 10 Nov 2025 |
| EPS Cair (TTM) | -3.75 |
| Nisbah Semasa (MRQ) | 26.48 |
| Aliran Tunai Operasi (OCF TTM) | -192.66 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -122.17 M |
| Pulangan Atas Aset (ROA TTM) | -35.87% |
| Pulangan Atas Ekuiti (ROE TTM) | -56.31% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Mineralys Therapeutics, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 4.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -0.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -0.5 |
| Purata | 0.75 |
|
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 1.40% |
| % Dimiliki oleh Institusi | 103.83% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 56.00 (HC Wainwright & Co., 29.15%) | Beli |
| Median | 55.00 (26.85%) | |
| Rendah | 52.00 (Goldman Sachs, 19.93%) | Beli |
| Purata | 54.33 (25.30%) | |
| Jumlah | 3 Beli | |
| Harga Purata @ Panggilan | 44.31 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 12 Nov 2025 | 56.00 (29.15%) | Beli | 47.33 |
| 30 Oct 2025 | 52.00 (19.93%) | Beli | 41.12 | |
| Wells Fargo | 11 Nov 2025 | 55.00 (26.85%) | Beli | 47.11 |
| 11 Sep 2025 | 50.00 (15.31%) | Beli | 37.16 | |
| Goldman Sachs | 09 Sep 2025 | 52.00 (19.93%) | Beli | 38.50 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |